GÖRG advises Heidelberg Pharma AG on a capital increase with gross proceeds of EUR 14.4 million
GÖRG Partnerschaft von Rechtsanwälten mbB advised Heidelberg Pharma AG on a capital increase with gross proceeds of EUR 14.4 million under the leadership of Munich partner Dr. Bernt Paudtke.
The capital increase based on resolutions of 27 April 2020 represents approximately 10% of the company’s out-standing share capital and will increase the total number of shares to 31,030,572. The 2,820,961 new shares were placed exclusively with the major shareholder dievini Hopp Biotech holding GmbH & Co. KG, Walldorf and institutional investors via an accelerated book building transaction and will be admitted to trading on the Frankfurt Stock Exchange. The issue price was EUR 5.10 per share, resulting in gross proceeds of EUR 14.4 million for Heidelberg Pharma AG.
The capital increase has been executed by MainFirst Bank AG acting as global coordinator and sole bookrunner.
Advisors Heidelberg Pharma
GÖRG Partnerschaft von Rechtsanwälten mbB
Dr. Bernt Paudtke, Partner, M&A / Corporate, Munich
Dr. Christian Glauer, Associated Partner, M&A / Corporate, Munich
Tobias Reichenberger, Associate, M&A / Corporate, Munich
Legal Department Heidelberg Pharma AG
Mikaela Dimitropoulos (Director Legal, HR & IP)
About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6.
